Difference between calculated and direct-measured low-density lipoprotein cholesterol in subjects with diabetes mellitus or taking lipid-lowering medications

被引:14
|
作者
Choi, Su-Yeon [2 ]
Park, Hyo Eun [2 ]
Kim, Min-Kyung [2 ]
Shin, Chan Soo [2 ]
Cho, Sang-Heon [2 ]
Oh, Byung-Hee [1 ]
机构
[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[2] Seoul Natl Univ Hosp, Dept Internal Med, Healthcare Syst Gangnam Ctr, Seoul 135984, South Korea
关键词
Low-density lipoprotein cholesterol; Friedewald formula; Diabetes mellitus; Triglyceride; Community-based study; CORONARY-HEART-DISEASE; ASSAY; RISK;
D O I
10.1016/j.jacl.2011.12.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: We evaluated factors that caused differences between calculated low-density lipoprotein cholesterol (C-LDL-C) and direct-measured LDL-C (D-LDL-C) and compared them in subjects with diabetes mellitus (DM) or taking lipid-lowering medications. METHODS: 21,452 subjects (9,177 women, 12,275 men; 8.1% with DM and 8.5% on lipid-lowering medications) were included in the analysis. Participants were classified into 3 groups, i.e., group 1: the subjects without DM and not on lipid-modifying drugs (n = 18,287), group 2: without DM and on lipid-modifying drugs (n = 1,423), and group 3: with DM (n = 1,742). LDL-C concentrations were either directly measured by a homogenous method or calculated by Friedewald formula. RESULTS: There was a significant correlation between C-LDL-C and D-LDL-C (r = 0.966, P < .001). The absolute values of the differences between two LDL-C values were 7.0 +/- 6.2 mg/dl and 6.6 +/- 7.3% (6.6 +/- 5.9 mg/dl and 6.0 +/- 6.5%, 8.8 +/- 6.7 mg/dl and 9.1 +/- 9.7%, and 10.1 +/- 7.3 mg/dl and 10.7 +/- 10.1% in group 1, 2, and 3 respectively, P < .001). The subjects with the absolute value of the differences of LDL-C >= 10% was 20.2% (17.3%, 31.3%, and 41.1% in group 1, 2, and 3 respectively, P < .001). In the multiple logistic regression analysis, high triglyceride (>= 150 mg/dl), low high-density lipoprotein cholesterol (HDL-C) (<40 mg/dl), male gender, obesity (body mass index >= 25 kg/m(2)), DM and taking lipid-lowering drugs were significant associated with high LDL-differences (the absolute value of the differences >= 10% or >= 10 mg/dl). CONCLUSION: D-LDL-C was generally higher by 5 mg/dl or 5% than C-LDL-C. The differences C-LDL-C and D-LDL-C were higher in subjects with DM and on lipid-lowering medications. Male gender, high triglyceride, low HDL-C, and obesity were also associated with the greater differences between C-LDL-C and D-LDL-C. (C) 2012 National Lipid Association. All rights reserved.
引用
收藏
页码:114 / 120
页数:7
相关论文
共 50 条
  • [21] Comparison of low-density lipoprotein cholesterol level calculated using the modified Martin/Hopkins estimation or the Friedewald formula with direct homogeneous assay measured low-density lipoprotein cholesterol
    Reiber, Istvan
    Mark, Laszlo
    Paragh, Gyorgy
    Toth, Peter
    ARCHIVES OF MEDICAL SCIENCE, 2022, 18 (03) : 577 - 586
  • [22] THE FRIEDEWALD-LEVY-FREDRICKSON FORMULA FOR CALCULATING LOW-DENSITY LIPOPROTEIN CHOLESTEROL, THE BASIS FOR LIPID-LOWERING THERAPY
    ROBERTS, WC
    AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (04): : 345 - 346
  • [23] Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review
    Navarese, Eliano P.
    Andreotti, Felicita
    Raggi, Paolo
    Kolodziejczak, Michalina
    Buffon, Antonino
    Bliden, Kevin
    Tantry, Udaya
    Kubica, Jacek
    Sardella, Gennaro
    Lauten, Alexander
    Agewall, Stefan
    Gurbel, Paul A.
    Brouwer, Marc A.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2019, 5 (01) : 47 - 54
  • [24] The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus
    Xiangming Hu
    Qunzhi Liu
    Xingyuan Guo
    Weimian Wang
    Bingyan Yu
    Beijia Liang
    Yingling Zhou
    Haojian Dong
    Jijin Lin
    Cardiovascular Diabetology, 21
  • [25] The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus
    Hu, Xiangming
    Liu, Qunzhi
    Guo, Xingyuan
    Wang, Weimian
    Yu, Bingyan
    Liang, Beijia
    Zhou, Yingling
    Dong, Haojian
    Lin, Jijin
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [26] Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy
    Grundy, SM
    CIRCULATION, 2002, 106 (20) : 2526 - 2529
  • [27] Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy
    Feeman, WE
    CIRCULATION, 2003, 107 (20) : E199 - E199
  • [28] Impact of Lowering Low-Density Lipoprotein Cholesterol with Contemporary Lipid-Lowering Medicines on Cognitive Function: A Systematic Review and Meta-Analysis
    Hangying Ying
    Jiacheng Wang
    Zhida Shen
    Meihui Wang
    Binquan Zhou
    Cardiovascular Drugs and Therapy, 2021, 35 : 153 - 166
  • [29] Impact of Lowering Low-Density Lipoprotein Cholesterol with Contemporary Lipid-Lowering Medicines on Cognitive Function: A Systematic Review and Meta-Analysis
    Ying, Hangying
    Wang, Jiacheng
    Shen, Zhida
    Wang, Meihui
    Zhou, Binquan
    CARDIOVASCULAR DRUGS AND THERAPY, 2021, 35 (01) : 153 - 166
  • [30] Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein
    Backes, JM
    Gibson, CA
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (03) : 523 - 526